^
    Back
    Association details:
    Biomarker:LINC00520 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    USCAP 2020
    Title:

    LINC00520 Promotes EGFR-TKIs Acquired Resistance in Non-Small Cell Lung Carcinoma

    Published date:
    03/04/2020
    Excerpt:
    More interestingly, higher LINC00520 TPM implies a worse survival rate in LUAD (DFS: HR=1.4, p =0.043, OS: HR=1.4, p =0.028)…LINC00520 is involved in acquired resistance of EGFR-TKIs in NSCLC.